Osteosarcoma

Common Name(s)

Osteosarcoma

Osteosarcoma is the most common cancerous (malignant) bone tumor in youth. The average age at diagnosis is 15. Boys and girls have a similar incidence of this tumor until late adolescence, at which time boys are more commonly affected. In rare cases, osteosarcoma occurs in adults. The cause of osteosarcoma is not known. In some cases, it runs in families, and at least one gene has been linked to increased risk. Although osteosarcoma tends to occur in the larger bones, such as the shin (near the knee), thigh (near the knee) and upper arm (near the shoulder), it can occur in any bone. A number of variants of osteosarcoma exist, including conventional types (osteoblastic, chondroblastic, and fibroblastic), telangiectatic, multifocal, parosteal, and periosteal.  Treatment usually starts after a biopsy of the tumor and includes chemotherapy followed by surgery.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Osteosarcoma" for support, advocacy or research.

Cancer Hope Network

To provide one-on-one support to people undergoing treatment for cancer and to their families. We provide this support by training individuals who have recovered from cancer and matching them with cancer patients currently undergoing a similar experience. Through this matching process, we strive to instill hope and to make a difference in their fight against cancer.

Last Updated: 29 Jul 2015

View Details
Logo
Sarcoma Alliance

The Sarcoma Alliance strives to improve the lives of people affected by sarcoma through accurate diagnosis, improved access to care, guidance, education and support.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Osteosarcoma" for support, advocacy or research.

Cancer Hope Network

To provide one-on-one support to people undergoing treatment for cancer and to their families. We provide this support by training individuals who have recovered from cancer and matching them with cancer patients currently undergoing a similar experience. Through this matching process, we strive to instill hope and to make a difference in their fight against cancer.

http://www.CancerHopeNetwork.org

Last Updated: 29 Jul 2015

View Details
Logo
Sarcoma Alliance

The Sarcoma Alliance strives to improve the lives of people affected by sarcoma through accurate diagnosis, improved access to care, guidance, education and support.

http://sarcomaalliance.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Osteosarcoma" returned 2194 free, full-text research articles on human participants. First 3 results:

Prognostic factors to survival of patients with chondroblastic osteosarcoma.
 

Author(s): Hui-Hui Sun, Xiang-Yang Chen, Jia-Qu Cui, Zhao-Ming Zhou, Kai-Jin Guo

Journal: Medicine (Baltimore). 2018 Sep;97(39):e12636.

 

This study was aimed to reveal the changes in survival rates and prognostic factors to survival of chondroblastic osteosarcoma (COS).Patients from the Surveillance, Epidemiology, and End Results (SEER) database were retrieved. Kaplan-Meier survival analysis and Cox proportional hazard ...

Last Updated: 31 Dec 1969

Go To URL
X-linked inhibitor of apoptosis protein inhibitor Embelin induces apoptosis via PI3K/Akt pathway and inhibits invasion in osteosarcoma cells.
 

Author(s): Hao Qian, Tao Huang, Yao Chen, Xiucheng Li, Weihua Gong, Guangjian Jiang, Wei Zhang, Shuo Cheng, Xuhui Li, Pengcheng Li

Journal: J Cancer Res Ther. 2018 Sep;14(Supplement):S648-S655.

 

Embelin is an active compound identified as a novel X-linked inhibitor of apoptosis protein (XIAP) inhibitor from the Embelia ribes that exhibits various medicinal effects including anti-inflammatory and anticancer activities. However, the therapeutic effect of Embelin to human osteosarcoma ...

Last Updated: 31 Dec 1969

Go To URL
Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
 

Author(s): Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang-Bae Kong, Won Seok Song, Wan Hyeong Cho, Jae-Soo Koh, Sang Moo Lim

Journal: Medicine (Baltimore). 2018 Sep;97(37):e12318.

 

We compared the usefulness of Tc-methyl diphosphonate (Tc-MDP) bone scintigraphy and F-fluorodeoxyglucose (FDG) for positron emission tomography/computed tomography (PET/CT) in predicting histologic response in patients with osteosarcoma receiving neoadjuvant chemotherapy (NAC).We ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Osteosarcoma" returned 120 free, full-text review articles on human participants. First 3 results:

Systematic meta-analysis of genetic variants associated with osteosarcoma susceptibility.
 

Author(s): Xinjia Wang, Zhenyu Liu

Journal: Medicine (Baltimore). 2018 Sep;97(38):e12525.

 

In the past decade, accumulated evidence has suggested that genetic variation is related to the pathogenesis of osteosarcoma. Although there are a large number of studies on the association between genetic variation and osteosarcoma, their results are inconsistent. To clarify these ...

Last Updated: 31 Dec 1969

Go To URL
Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma.
 

Author(s): Yucheng Fu, Tao Lan, Hongliu Cai, Anwei Lu, Wei Yu

Journal: Medicine (Baltimore). 2018 May;97(19):e0741.

 

A large number of studies have reported the relationships between serum lactate dehydrogenase (LDH) and prognosis of osteosarcoma. However, the result is still controversial and no consensus has been reached. Therefore, we performed a meta-analysis to evaluate the prognostic role ...

Last Updated: 31 Dec 1969

Go To URL
GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance.
 

Author(s): Mihwa Kim, Dae Joon Kim

Journal:

 

The glycosylphosphatidylinositol-linked GDNF (glial cell derived neurotrophic factor) receptor alpha (GFRA), a coreceptor that recognizes the GDNF family of ligands, has a crucial role in the development and maintenance of the nervous system. Of the four identified GFRA isoforms, ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

The Osteosarcoma Biobank in Peking University People's Hospital
 

Status: Not yet recruiting

Condition Summary: Osteosarcoma

 

Last Updated: 2 Dec 2017

Go to URL
Biology of Osteosarcoma (BOOST) Registry and Biobank
 

Status: Recruiting

Condition Summary: Osteosarcoma

 

Last Updated: 21 Jul 2017

Go to URL
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
 

Status: Recruiting

Condition Summary: Osteosarcoma

 

Last Updated: 20 Jun 2018

Go to URL